Tenaya Therapeutics, Inc. (TNYA)
$0.69-$0.01 (-0.73%) Today
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
https://www.tenayatherapeutics.comSEC filings for TNYA on EDGAR
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 8 | 29,656 | $21K |
| Grant or award | 1 | 1,650,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
38 Form 4 filings on record, the earliest from Oct 21, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| David V. Goeddel | Grant or award | Stock Option (Right to buy) | 34,000 | $0.00 | - | |
 Karah Herdman Parschauer | Grant or award | Stock Option (Right to buy) | 34,000 | $0.00 | - | |
| June Lee | Grant or award | Stock Option (Right to buy) | 34,000 | $0.00 | - | |
| Catherine Stehman-Breen | Grant or award | Stock Option (Right to buy) | 34,000 | $0.00 | - | |
| Deepak Srivastava | Grant or award | Stock Option (Right to buy) | 34,000 | $0.00 | - | |
| Amy L. Burroughs | Grant or award | Stock Option (Right to buy) | 34,000 | $0.00 | - | |
| R. Sanders Williams | Grant or award | Stock Option (Right to buy) | 34,000 | $0.00 | - | |
| Jeffrey T. Walsh | Grant or award | Stock Option (Right to buy) | 34,000 | $0.00 | - |
This is as far as the anonymous view goes. Create a free account for all 38 TNYA filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Whittemore Tingley | Officer | 7,424 | $5K | View on EDGAR | |
| Faraz Ali | Officer, Director | 22,232 | $16K | View on EDGAR |
Tenaya Therapeutics, Inc. (TNYA) had 3 insider filings in the last 90 days, with the most recent on 2026-08-18. The full record for TNYA runs to 38 Form 4 filings, the earliest from 2024-10-21. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of TNYA were filed in the last 90 days.
8 insider sales of TNYA were filed in the last 90 days, totaling $21K.
This page tracks TNYA Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add TNYA to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
